Semaglutide, a glucagon-like peptide-1 receptor agonist, was primarily a drug in diabetes therapy that was subsequently FDA approved for long-term weight management, cardiovascular risk reduction and nonalcoholic fatty liver disease in patients with HIV.
The FDA permits the compounding of GLP-1 due to shortages but only if the product is compounded by pharmacies following the regulations contained in Section 503A of the Federal Food, Drug and Cosmetic Act (FD&C Act).In this article we will cover how to obtain Compounded GLP-1 (CS), its potential side effects, who is eligible for using CS for weight loss and what are unauthorized forms of CS.
